MKI67 and breast carcinoma: The collective evidence from the P024 [30], IMPACT [31], and ACOSOG Z1031 (Alliance) [32] trials showed that treatment-induced reduction in Ki-67 level in post-menopausal ER+ breast cancer patients is associated with disease-free (DFS) and relapse-free survival (RFS).